Reuters logo
BRIEF-Crispr Therapeutics, Casebia Therapeutics announce exclusive development and option agreement with Stridebio
2017年4月17日 / 下午12点32分 / 5 个月前

BRIEF-Crispr Therapeutics, Casebia Therapeutics announce exclusive development and option agreement with Stridebio

April 17 (Reuters) - Crispr Therapeutics Ag

* Crispr Therapeutics and Casebia Therapeutics announce exclusive development and option agreement with Stridebio

* Crispr Therapeutics - under agreement, Stridebio will use proprietary platform to develop AAV vectors with improved properties

* Crispr Therapeutics - co, Casebia will have option to exclusively license aav vectors with desired properties for use in their in Vivo gene-editing programs

* Stridebio will receive development funding, milestones and royalties on licensed vectors

* Stridebio will retain certain rights to use Novel aav vectors for gene therapy applications Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below